BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND TSC1, KIAA0243, 7248, ENSG00000165699, TSC, MGC86987, LAM, hamartin AND Prognosis
10 results:

  • 1. Turning up the heat on non-immunoreactive tumors: autophagy influences the immune microenvironment in pancreatic cancer.
    Lu SY; Hua J; Liu J; Wei MY; Liang C; Meng QC; Zhang B; Yu XJ; Wang W; Xu J
    BMC Med Genomics; 2022 Oct; 15(1):218. PubMed ID: 36261830
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in pancreatic Adenocarcinoma.
    Duan Y; Du Y; Gu Z; Zheng X; Wang C
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142223
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low tsc1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.
    Ye Q; Ling S; Jiang G; Shan Q; Xu S; Zhan Q; Wu Y; Liu Y; Zheng S; Xu X
    Eur J Surg Oncol; 2021 Oct; 47(10):2533-2542. PubMed ID: 33902956
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Inherited tumor syndromes of gastroenteropancreatic and thoracic neuroendocrine neoplasms].
    Couvelard A; Scoazec JY
    Ann Pathol; 2020 Apr; 40(2):120-133. PubMed ID: 32035641
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Expression of La Ribonucleoprotein Domain Family Member 4B (LARP4B) in Liver cancer and Their Clinical and Prognostic Significance.
    Li Y; Jiao Y; Li Y; Liu Y
    Dis Markers; 2019; 2019():1569049. PubMed ID: 31772683
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.
    Williamson LM; Steel M; Grewal JK; Thibodeau ML; Zhao EY; Loree JM; Yang KC; Gorski SM; Mungall AJ; Mungall KL; Moore RA; Marra MA; Laskin J; Renouf DJ; Schaeffer DF; Jones SJM
    Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160355
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
    Scarpa A
    Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma.
    Kong B; Cheng T; Qian C; Wu W; Steiger K; Cao J; Schlitter AM; Regel I; Raulefs S; Friess H; Erkan M; Esposito I; Kleeff J; Michalski CW
    Mol Cancer; 2015 Dec; 14():212. PubMed ID: 26683340
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Death-associated protein kinase 1 promotes growth of p53-mutant cancers.
    Zhao J; Zhao D; Poage GM; Mazumdar A; Zhang Y; Hill JL; Hartman ZC; Savage MI; Mills GB; Brown PH
    J Clin Invest; 2015 Jul; 125(7):2707-20. PubMed ID: 26075823
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2011 Mar; 12(2):117-9. PubMed ID: 21386634
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.